US 2011/0301080 A1Published application

Pharmaceutical compositions

AssigneeGlaxoSmithKline LLC

InventorsMark A. Bush, Murray W. Stewart, Yonghong Yang

Life of this patent

Estimating the term…

Abstract

The present invention provides pharmaceutical compositions comprising at least one polypeptide having GLP-1 activity wherein an effective dose of said pharmaceutical composition comprises 15 mg, 30 mg, 50 mg or 100 mg of said polypeptide having GLP-1 activity. Also provided are methods of administering the pharmaceutical compositions of the invention.

Claims34

Dependent claims

A pharmaceutical composition comprising at least one polypeptide having GLP-1 activity wherein an effective dose of said pharmaceutical composition comprises 15 mg, 30 mg, 50 mg or 100 mg of said polypeptide having GLP-1 activity.

Dependencies are inferred from the claim text.

Facts

Application: 13/133,976Filed 10 Dec 2009
Priority: 10 Dec 2008
Published: 8 Dec 2011
Term ends: Not estimatedThe source records don’t support an estimate.

Classification11 codes

A61K 38/26
Hormones: glucagons
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61P 3/04
Drugs for disorders of the metabolism: anorexiants; Antiobesity agents
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics

Family

Application61/121,229Us provisional application · filed 10 Dec 2008
Application61/150,909Us provisional application · filed 9 Feb 2009
Application61/163,995Us provisional application · filed 27 Mar 2009
Application61/238,723Us provisional application · filed 1 Sep 2009
US 8,748,377 B2Related patent
US 2011/0301080 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results